不可治愈头颈鳞癌姑息放疗方案的随机对照试验
该随机对照试验比较两种姑息放疗方案(36 Gy/6次、每周2次 与 50 Gy/16次、每周4次)在不可治愈局部晚期或有限转移性头颈鳞癌中的疗效、毒性与生活质量。因入组缓慢提前终止,仅纳入34例;两组客观缓解率、局部区域控制与总生存均无显著差异,但短程方案急性≥3级毒性和3级口腔黏膜炎显著更低。
要点
- 短程36 Gy/6次与长程50 Gy/16次在肿瘤学结局上无显著差异。
- 短程组急性≥3级毒性16.7%,显著低于长程组57.1%。
- 因样本量不足、统计效能不够,结论需谨慎解读。
核心结论
- 因研究提前终止且样本量不足,无法得出确切结论;长程放疗未显示显著更好的肿瘤学结局,但伴更多急性3级口腔黏膜炎,生活质量评分无显著差异,可谨慎考虑较短方案。
研究设计与样本
- 随机对照试验,1:1分配至36 Gy/6次(每周2次)或50 Gy/16次(每周4次);因入组缓慢提前终止,共纳入34例局部晚期不可根治或有限转移性头颈鳞癌患者。
主要发现
- 客观缓解率短程组38.9%、长程组57.1%(p=0.476)。
- 1年局部区域控制率短程组57.4%、长程组69.3%(p=0.450,HR=0.56,95%CI 0.12-2.58)。
- 1年总生存率短程组33.3%、长程组57.1%,中位生存分别为35.4周和59.5周(p=0.215,HR=0.55,95%CI 0.21-1.43)。
- 急性≥3级毒性短程组16.7%、长程组57.1%(p=0.027),3级口腔黏膜炎分别为5.6%和42.9%(p=0.027)。
- 患者报告的生活质量各量表均未发现显著恶化。
关键数值与推荐
- 短程方案:36 Gy分6次,每周2次;长程方案:50 Gy分16次,每周4次。
- 急性≥3级毒性短程组16.7%对长程组57.1%(p=0.027);3级口腔黏膜炎5.6%对42.9%(p=0.027)。
临床怎么用
- 对不可治愈头颈鳞癌行姑息放疗时,可谨慎考虑短程36 Gy/6次方案以减少急性黏膜毒性,但需向患者说明证据效能不足。
局限性
- 试验因入组缓慢提前终止,仅34例,统计效能不足,肿瘤学结局比较可能不准确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No randomized controlled trials (RCT) have yet identified the optimal palliative radiotherapy scheme in patients with incurable head and neck squamous cell carcinoma (HNSCC). We conducted RCT to compare two radiation schemes in terms of efficacy, toxicity and quality-of-life (QoL). MATERIALS AND METHODS: Patients with locally-advanced HNSCC who were ineligible for radical treatment and those with limited metastatic disease were randomly assigned in 1:1 ratio to arm 1 (36 Gy in 6 fractions, twice a week) or arm 2 (50 Gy in 16 fractions, four times a week). RESULTS: The trial was discontinued early because of slow accrual (34 patients enrolled). Objective response rates were 38.9% and 57.1% for arm 1 and 2 respectively (p = 0.476). The median time to loco-regional progression was not reached. The loco-regional control rates at 1 year was 57.4% and 69.3% in arm 1 and 2 (p = 0.450, HR = 0.56, 95%CI 0.12-2.58). One-year overall survival was 33.3% and 57.1%, with medians of 35.4 and 59.5 weeks, respectively (p = 0.215, HR = 0.55, 95%CI 0.21-1.43). Acute grade ≥3 toxicity was lower in arm 1 (16.7% versus 57.1%, p = 0.027), with the largest difference in grade 3 mucositis (5.6% versus 42.9%, p = 0.027). However, no significant deterioration in any of the patient-reported QoL-scales was found. CONCLUSION: No solid conclusion could be made on this incomplete study which is closed early. Long-course radiotherapy did not show significantly better oncologic outcomes, but was associated with more acute grade 3 mucositis. No meaningful differences in QoL-scores were found. Therefore, the shorter schedule might be carefully advocated. However, this recommendation should be interpreted with great caution because of the inadequate statistical power.
引用
- Al-Mamgani A, Kessels R, Verhoef CG, et al. Randomized controlled trial to identify the optimal radiotherapy scheme for palliative treatment of incurable head and neck squamous cell carcinoma. Radiother Oncol. 2020. PMID: 32417345. doi:10.1016/j.radonc.2020.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。